Objective: To evaluate the prevalence of the urinary excretion of BKV and JCV in HIV-infected patients without neurological symptoms.

Methods: Urine samples from HIV-infected patients without neurological symptoms were tested for JC virus and BK virus by PCR. Samples were screened for the presence of polyomavirus with sets of primers complementary to the early region of JCV and BKV genome (AgT). The presence of JC virus or BK virus were confirmed by two other PCR assays using sets of primers complementary to the VP1 gene of each virus. Analysis of the data was performed by the Kruskal-Wallis test for numerical data and Pearson or Yates for categorical variables.

Results: A total of 75 patients were included in the study. The overall prevalence of polyomavirus DNA urinary shedding was 67/75 (89.3%). Only BKV DNA was detected in 14/75 (18.7%) urine samples, and only JCV DNA was detected in 11/75 (14.7%) samples. Both BKV and JCV DNA were present in 42/75 (56.0%) samples.

Conclusion: In this study we found high rates of excretion of JCV, BKV, and simultaneous excretion in HIV+ patients. Also these results differ from the others available on the literature.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0036-46652012000400004DOI Listing

Publication Analysis

Top Keywords

hiv-infected patients
12
patients neurological
12
simultaneous excretion
8
neurological symptoms
8
bkv jcv
8
urine samples
8
virus virus
8
sets primers
8
primers complementary
8
jcv bkv
8

Similar Publications

[Exploring the mechanism of HIV infection on T lymphocyte mitochondrial damage based on MAPK pathway].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

December 2024

Department of Infection and Immunology, Changsha First Hospital, Changsha 410005, China.

Objective To clarify the mechanism that HIV infection mediates mitochondrial damage of CD4 T lymphocytes (CD4 T cells) through mitogen-activated protein kinase (MAPK) pathway. Methods From October 1st, 2022 to March 31st, 2023, 47 HIV-infected people who received antiretroviral therapy (ART) for 4 years were recruited, including 22 immune non-responders (INR) and 25 responders (IR); and 26 sex and age-matched control participants (HC) who were negative for HCV, HBV, and HIV infections. The immune parameters were analyzed by flow cytometry.

View Article and Find Full Text PDF

HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.

Glob Health Med

December 2024

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen.

View Article and Find Full Text PDF

Myelopathy as the first manifestation of AIDS.

AIDS Res Ther

December 2024

Department of Neurology, Xi'an International Medical Center Hospital, xitai road, gaoxin District, Xi'an city, Shaanxi Province, China.

Background: Human immunodeficiency virus (HIV) is a retrovirus mainly infecting immune cells. Central nervous system diseases in HIV-infected patients can be caused by HIV or opportunistic infections. Neurological diseases associated with HIV have diverse manifestations and may occur in early or late stages.

View Article and Find Full Text PDF

Background: Human immunodeficiency virus (HIV) is a lentivirus. It is transmitted through sexual intercourse, shared intravenous drugs, contaminated needle use, blood transfusion, and mother-to-child transmission. Of the patients with HIV, 50%-75% have ocular manifestations and this may be the primary presentation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!